Price Action To Observe: Could Viewray Inc Decline After Today’s Significant Increase?

Price Action To Observe: Could Viewray Inc Decline After Today's Significant Increase?

The stock of Viewray Inc (NASDAQ:VRAY) is a huge mover today! About 79,881 shares traded hands. Viewray Inc (NASDAQ:VRAY) has declined 13.68% since March 7, 2016 and is downtrending. It has underperformed by 21.28% the S&P500.
The move comes after 7 months positive chart setup for the $177.75M company. It was reported on Oct, 10 by Barchart.com. We have $12.42 PT which if reached, will make NASDAQ:VRAY worth $346.61M more.

Analysts await Viewray Inc (NASDAQ:VRAY) to report earnings on November, 14. They expect $-0.28 earnings per share, up 20.00% or $0.07 from last year’s $-0.35 per share. After $-0.32 actual earnings per share reported by Viewray Inc for the previous quarter, Wall Street now forecasts -12.50% EPS growth.

According to Zacks Investment Research, “ViewRay Inc. is a medical device company. The company develops advanced radiation therapy technology for the treatment of cancer. MRIdian system provides continuous soft-tissue imaging during treatment. ViewRay Inc. is headquartered in Oakwood Village, Ohio.”

More notable recent Viewray Inc (NASDAQ:VRAY) news were published by: Prnewswire.com which released: “ViewRay Reports Second Quarter 2016 Financial Results” on August 15, 2016, also Crainscleveland.com with their article: “ViewRay Inc. approved to list its stock on the NASDAQ Global Market” published on March 29, 2016, Crainscleveland.com published: “ViewRay Inc. files to raise up to $69 million in initial public offering” on March 06, 2015. More interesting news about Viewray Inc (NASDAQ:VRAY) were released by: Prnewswire.com and their article: “ViewRay┬« Appoints Ajay Bansal as Chief Financial Officer” published on June 09, 2016 as well as Crainscleveland.com‘s news article titled: “ViewRay raises $13.75 million in private placement deal” with publication date: August 22, 2016.

VRAY Company Profile

ViewRay, Inc., incorporated on October 6, 2013, through its subsidiary ViewRay Technologies, Inc., designs, makes and markets MRIdian, the magnetic resonance imaging (MRI)-guided radiation therapy system to image and treat cancer patients simultaneously. The Firm offers radiation therapy technology combined with magnetic resonance imaging. MRIdian integrates MRI technology, radiation delivery and the Company’s software to locate, target and track the position and shape of soft-tissue tumors while radiation is delivered.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Leave a Comment